Sanofi Gross Margin 2012-2026 | SNY
Current and historical gross margin for Sanofi (SNY) over the last 10 years. The current gross profit margin for Sanofi as of March 31, 2026 is %.
| Sanofi Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2026-03-31 | $54.84B | $39.45B | 71.93% |
| 2025-12-31 | $52.85B | $38.09B | 72.07% |
| 2025-09-30 | $46.78B | $33.96B | 72.60% |
| 2025-06-30 | $46.96B | $33.63B | 71.63% |
| 2025-03-31 | $47.02B | $33.43B | 71.08% |
| 2024-12-31 | $47.92B | $33.63B | 70.18% |
| 2024-09-30 | $53.03B | $36.77B | 69.34% |
| 2024-06-30 | $51.29B | $35.34B | 68.91% |
| 2024-03-31 | $50.68B | $34.84B | 68.75% |
| 2023-12-31 | $50.27B | $34.86B | 69.35% |
| 2023-09-30 | $49.01B | $34.08B | 69.53% |
| 2023-06-30 | $48.42B | $33.81B | 69.83% |
| 2023-03-31 | $48.20B | $33.70B | 69.91% |
| 2022-12-31 | $47.82B | $33.39B | 69.83% |
| 2022-09-30 | $48.72B | $34.35B | 70.51% |
| 2022-03-31 | $34.76B | $24.48B | 70.41% |
| 2021-09-30 | $35.03B | $24.26B | 69.26% |
| 2021-03-31 | $43.57B | $29.98B | 68.80% |
| 2020-09-30 | $42.75B | $29.42B | 68.82% |
| 2020-03-31 | $41.19B | $28.45B | 69.06% |
| 2019-09-30 | $41.49B | $28.27B | 68.15% |
| 2019-03-31 | $41.50B | $28.41B | 68.47% |
| 2018-03-31 | $41.43B | $28.14B | 67.93% |
| 2017-12-31 | $40.92B | $27.80B | 67.93% |
| 2017-09-30 | $40.25B | $27.56B | 68.47% |
| 2017-06-30 | $39.59B | $27.15B | 68.59% |
| 2017-03-31 | $39.14B | $27.03B | 69.06% |
| 2016-12-31 | $38.41B | $26.57B | 69.17% |
| 2016-09-30 | $39.27B | $27.29B | 69.49% |
| 2016-06-30 | $39.37B | $27.23B | 69.17% |
| 2016-03-31 | $41.16B | $28.29B | 68.75% |
| 2015-09-30 | $42.97B | $29.31B | 68.22% |
| 2015-06-30 | $43.92B | $30.08B | 68.50% |
| 2014-06-30 | $44.70B | $30.67B | 68.62% |
| 2013-06-30 | $45.22B | $31.02B | 68.59% |
| 2012-06-30 | $46.75B | $31.94B | 68.33% |
| 2012-03-31 | $47.10B | $31.70B | 67.31% |
| 2011-12-31 | $47.27B | $32.09B | 67.88% |
| 2011-09-30 | $45.65B | $31.06B | 68.05% |
| 2011-06-30 | $44.35B | $30.90B | 69.68% |
| 2011-03-31 | $42.93B | $30.94B | 72.07% |
| 2010-12-31 | $41.26B | $29.68B | 71.95% |
| 2010-09-30 | $41.28B | $29.76B | 72.09% |
| 2010-06-30 | $41.42B | $29.96B | 72.33% |
| 2010-03-31 | $41.35B | $30.02B | 72.59% |
| 2009-12-31 | $40.79B | $29.80B | 73.06% |
| 2009-09-30 | $40.53B | $30.07B | 74.20% |
| 2009-06-30 | $39.73B | $29.47B | 74.18% |
| 2009-03-31 | $39.56B | $29.12B | 73.62% |
| 2008-12-31 | $40.89B | $30.09B | 73.60% |
| 2008-09-30 | $41.42B | $30.35B | 73.28% |
| 2008-06-30 | $41.43B | $30.44B | 73.49% |
| 2008-03-31 | $40.37B | $29.61B | 73.34% |
| 2007-12-31 | $39.59B | $29.22B | 73.79% |
| 2007-09-30 | $38.72B | $28.63B | 73.95% |
| 2007-06-30 | $37.43B | $27.61B | 73.76% |
| 2007-03-31 | $36.97B | $27.25B | 73.71% |
| 2006-12-31 | $35.70B | $26.17B | 73.30% |
| 2006-09-30 | $34.55B | $24.86B | 71.96% |
| 2006-06-30 | $34.49B | $25.18B | 73.00% |
| 2006-03-31 | $34.02B | $24.74B | 72.74% |
| 2005-12-31 | $33.98B | $24.55B | 72.26% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |